HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

AMGN — Amgen Inc.

AMGN (Amgen Inc.) stock: $460.42, $249.05B market cap, $25.81B cash, $277.24B EV, $255.21B fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies.

Source: 10-K FY2025 via SEC EDGAR

Share price
$460.42
Market cap
$249,046.5M
Cash
$25,811.0M
Enterprise value
$277,242.5M

Balance sheet

Cash$25,811.0M
Debt$54,007.0M
Net cash-$28,196.0M
Enterprise value$277,242.5M
Basic shares540.9M shares
Fully diluted shares554.3M shares
Fully diluted market cap$255,214.5M
Cash per share$47.72
Quarterly burn+$4,002.0M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common
540.6M
Pre-funded warrants
0.0M
Options
6.1M
RSUs
3.8M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
3.8M
FDSO
554.3M

Cap table as of 2026-06-30.

Price history

Loading AMGN daily closes…

Loading price history…

Next catalyst

Maridebart Cafraglutide · Now - Nov 18, 2026 Now · Phase 1 · Overweight; Obesity

Recently reported

Tarlatamab Phase 3 Positive · 2026-10-24
Primary: Overall survival (OS) in the Phase 3 DeLLphi-305 study of IMDELLTRA in combination with durvalumab versus durvalumab alone as first-line maintenance in extensive stage small cell lung cancer (ES-SCLC) — IMDELLTRA in combination with durvalumab reduced the risk of death by 58% (hazard ratio [HR]: 0.42; 95% confidence interval [CI]: 0.32, 0.54; P < 0.001), extending median overall survival (OS) to 21.1 months compared with 12.7 months with durvalumab alone
· At one year, nearly 80% of patients treated with IMDELLTRA in combination with durvalumab remained alive compared to 53% with durvalumab alone
· Reduced the risk of disease progression or death by 66% (HR: 0.34; 95% CI: 0.28, 0.42; P < 0.001), with a median progression-free survival of 7.4 months versus 1.9 months
· Objective response 26.4% (95% CI: 20.9, 32.5) compared with durvalumab alone (4.1%; 95% CI: 2.0, 7.4)
· DeLLphi-303 longer follow-up: median OS was 37.9 months from the start of first-line maintenance therapy with IMDELLTRA plus standard-of-care anti-PD-L1 therapy
· DeLLphi-304 update: patients receiving IMDELLTRA lived 13.6 versus 8.4 months, with a 38% reduction in the risk of death (HR 0.62; 95% CI, 0.51–0.76)
· 563 patients were randomized in DeLLphi-305
Safety: Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 20.9% of patients treated with IMDELLTRA in combination with durvalumab and 10.8% with durvalumab alone; cytokine release syndrome (CRS) was reported in 49.6% of patients who received IMDELLTRA, predominantly Grade 1 (41.8%) or Grade 2 (7.4%) with only one Grade 3 event (0.4%) and no Grade 4 or greater events; immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 1.1%, with no Grade 3 or higher ICANS events
Source release →
Dazodalibep Phase 3 Positive · 2026-09-22
OASIZ 301 · sjögren's syndrome (ss)
Source release →
sibeprenlimab Phase 3 Mixed · 2026-06-30
VISIONARY · IgA nephropathy
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego